May 03, 2018
PARIS & SAN FRANCISCO–(BUSINESS WIRE)–Regulatory News:
SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that develops and markets instruments designed to secure the placement of surgical implants by bringing real-time digital technology into the operating room, announced today it has been granted a second patent by the US Patent Office for the application of its Dynamic Surgical Guidance technology for a new application: bone quality measurement, in this particular patent with a focus on monitoring the consolidation of the bony fusion bed.
Stéphane Bette, CEO and co-founder of SpineGuard, said: “The success of skeletal fixation procedures is based on obtaining a solid bony fusion providing long-term stability of the repair, thanks to the implants that are inserted internally to hold the bone structures in place while they fuse. We believe that the DSG® technology can allow real-time in-situ monitoring of the progress of the bony fusion. This exciting new patent granted in the USA is one more illustration that our core technology is a platform that has multiple applications; our company is constantly innovating and working at providing valuable digital information about the health status of patients.”
“The potential applications of in-situ monitoring of the bony fusion are multiple in the post-operative phase: from the adaptation of the physical therapy, the adjustment of the stiffness of braces, to the connection with the implants themselves to make them smart and adapting to the bone healing status.” concluded Maurice Bourlion, Co-inventor of the DSG® technology and Director of SpineGuard.
More information on the DSG® technology, its new applications and surgeons’ testimonials here.
Next financial press release: 2018 Half-year revenue: July 11, 2018
About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer by bringing real-time digital technology into the operating room. Its primary objective is to establish its proprietary DSG® (Dynamic Surgical Guidance) technology as the global standard of surgical care, starting with safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG, was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 60,000 surgical procedures have been performed worldwide with DSG® enabled devices. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard® delivers to patients, surgical staff and hospitals. SpineGuard is expanding the scope of its DSG® platform through strategic partnerships with innovative medical device companies and the development of smart instruments and implants. SpineGuard has offices in San Francisco and Paris. For further information, visit www.spineguard.com.
Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
Contacts
SpineGuard
Stéphane Bette, +33 (0)1 45 18 45 19
Chief Executive Officer
s.bette@spineguard.com
or
Manuel Lanfossi
Chief Financial Officer
m.lanfossi@spineguard.com
or
Europe / NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel: +33 (0)1 44 71 94 94
spineguard@newcap.eu